SBIR/STTR Research Award
Novel mechanism-based targeted approach to rheumatoid arthritis
Award amount
$223,013Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- SIGNABLOK, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- JM5UN38YM1H7
- Solicitation number
- PA14-071
- Topic code
- NIAMS
Research abstract
DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that causes chronic inflammation of the joints. RA affects about 1.5 million Americans and costs society more than 40 billion each year. Despite advances in therapy, RA has no cure. Current treatments of RA include non-steroidal anti- inflammatory drugs, corticosteroids, and disease modifying anti-rheumatic drugs (DMARDs). They all have multiple shortcomings including a high level of serious side effects and insufficient efficacy. Methotrexate (MTX), a folate antagonist that blocks folic acid activity, is the most widely used non-biologic DMARD. However, its significant toxicity which is usually related to the dose taken drastically limits its clinical use and is the most common cause of discontinuing MTX therapy. Biologic DMARDs include tumor necrosis factor (TNF) blockers such as Humira. TNF blockers may cause serious side effects such as infections and malignancies. This highlights the need for
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- TREM-1 therapy for the treatment of empyema
- First-in-class TREM-1 inhibitors for neovascular retinal diseases
- First-in-class TREM-1 inhibitors for neovascular retinal diseases
- New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
- First-in-class TREM-1 Radioprotector to Prevent the Effects of Acute Radiation Syndrome
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Smart Cavity Creator Drill for Lumbar Interbody Fusion: Direct to Phase II
- Use of HIF-1alpha mRNA to Promote Pedicle Flap Healing.
- Development of novel genetic medicine approaches to treat orphan diseases
- A novel agent for preventing fatty degeneration of muscles in LGMD2B
- Bispecific biologic for rheumatoid arthritis therapy
Research funding history
17 SBIR/STTR records share this UEI (2012–2025). Reported award amounts total $7,696,076. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, Department of Defense